Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + docetaxel + pemetrexed
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of apatinib (an oral VEGFR-2 tyrosine kinase inhibitor), docetaxel (a cytotoxic chemotherapy agent), and pemetrexed (an antifolate antineoplastic agent). Based on the search results, this specific three-drug combination is not commonly used or described as a standard regimen. However, combinations of apatinib + docetaxel and apatinib + pemetrexed have shown promising efficacy in treating advanced non-small cell lung cancer (NSCLC), particularly in patients with brain metastasis. The individual drugs are well-established treatments for various cancers, including NSCLC.
02
Targets
GART (GAR transformylase)SRC (Proto-oncogene tyrosine-protein kinase Src)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on apatinib + docetaxel + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + docetaxel + pemetrexed.